Patents by Inventor Joachim Nozulak

Joachim Nozulak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZISOXAZOLES
    Publication number: 20200131166
    Abstract: The present invention relates to novel fatty acid esters of the reversible Iloperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
    Type: Application
    Filed: December 26, 2019
    Publication date: April 30, 2020
    Inventors: Joachim Nozulak, Hans Kalkman
  • BENZISOXAZOLES
    Publication number: 20190276444
    Abstract: The present invention relates to novel fatty acid esters of the reversible Iloperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
    Type: Application
    Filed: May 28, 2019
    Publication date: September 12, 2019
    Inventors: Joachim Nozulak, Hans Kalkman
  • BENZISOXAZOLES
    Publication number: 20190055228
    Abstract: The present invention relates to novel fatty acid esters of the reversible Iloperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Inventors: Joachim Nozulak, Hans Kalkman
  • BENZISOXAZOLES
    Publication number: 20180118729
    Abstract: The present invention relates to novel fatty acid esters of the reversible Iloperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
    Type: Application
    Filed: November 24, 2017
    Publication date: May 3, 2018
    Inventors: Joachim Nozulak, Hans Kalkman
  • Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
    Patent number: 9670193
    Abstract: The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or diabetes/metabolic syndrome via inhibition of HDAC4.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: June 6, 2017
    Assignee: Novartis AG
    Inventors: Christina Hebach, Joerg Kallen, Joachim Nozulak, Marina Tintelnot-Blomley, Leo Widler
  • BENZISOXAZOLES
    Publication number: 20170129878
    Abstract: The present invention relates to novel fatty acid esters of the reversible Iloperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
    Type: Application
    Filed: January 20, 2017
    Publication date: May 11, 2017
    Inventors: Joachim Nozulak, Hans Kalkman
  • 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
    Patent number: 9067881
    Abstract: The invention relates to compounds of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: June 30, 2015
    Assignee: NOVARTIS AG
    Inventors: Joachim Nozulak, Dieter Oser
  • NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20140329825
    Abstract: The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or diabetes/metabolic syndrome via inhibition of HDAC4.
    Type: Application
    Filed: November 26, 2012
    Publication date: November 6, 2014
    Applicant: NOVARTIS AG
    Inventors: Christina Hebach, Joerg Kallen, Joachim Nozulak, Marina Tintelnot-Blomley, Leo Widler
  • Use of 1H-Quinazoline-2,4-Diones
    Publication number: 20140018376
    Abstract: The invention concerns the use of competitive AMPA receptor antagonists for the treatment, prevention or delay of progression of Rasmussen's encephalitis and/or certain forms of epilepsy.
    Type: Application
    Filed: October 20, 2010
    Publication date: January 16, 2014
    Inventors: Hans Allgeier, Yves Auberson, Thomas Blaettler, David Carcache, Philipp Floersheim, Wolfgang Froestl, Christel Guibourdenche, Hans o Kalkman, Joerg Kallen, Manuel Koller, Kurt Lingenhohl, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud, Christine Strohmaier
  • 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives
    Publication number: 20130303538
    Abstract: The invention relates to compounds of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them.
    Type: Application
    Filed: January 20, 2012
    Publication date: November 14, 2013
    Inventors: Joachim Nozulak, Dieter Oser
  • 1H-QUINAZOLINE-2,4-DIONES
    Publication number: 20130296332
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: July 1, 2013
    Publication date: November 7, 2013
    Inventors: Hans ALLGEIER, Yves AUBERSON, David CARCACHE, Philipp FLOERSHEIM, Christel GUIBOURDENCHE, Wolfgang FROESTL, Jörg KALLEN, Manuel KOLLER, Henri MATTES, Joachim NOZULAK, David ORAIN, Johanne RENAUD
  • 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy
    Patent number: 8513268
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: August 20, 2013
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES
    Publication number: 20130053381
    Abstract: The invention relates to a 2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl-sulfonamide derivative being (A) a compound of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; or (B) a compound selected from a certain group of 2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl-sulfonamide derivatives disclosed in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them. In a first aspect, the invention provides prodrugs of AMPA receptor antagonists which potentially useful in the treatment of a wide range of disorders, particularly epilepsy.
    Type: Application
    Filed: May 18, 2011
    Publication date: February 28, 2013
    Inventors: Yves Auberson, David Carcache, Andreas Lerchner, Joachim Nozulak
  • Quinazoline derivatives
    Patent number: 8299085
    Abstract: The present invention relates to 1H-Quinazoline-2,4-dione derivatives of formula(I) wherein the substituents are defined as in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: October 30, 2012
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Wolfgang Froestl, Manuel Koller, Henri Mattes, Joachim Nozulak, Silvio Ofner, David Orain, Vittorio Rasetti, Johanne Renaud, Nicolas Soldermann, Philipp Floersheim
  • Organic Compounds
    Publication number: 20110294799
    Abstract: The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: August 12, 2008
    Publication date: December 1, 2011
    Inventors: Samuel Hintermann, Konstanze Hurth, Joachim Nozulak, Marina Tintelnot-Blomley
  • 1H-QUINAZOLINE-2,4-DIONES
    Publication number: 20110294818
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Application
    Filed: July 28, 2011
    Publication date: December 1, 2011
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide
    Patent number: 8012988
    Abstract: The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: September 6, 2011
    Assignee: Novartis AG
    Inventors: Hans Allgeier, Yves Auberson, David Carcache, Philipp Floersheim, Christel Guibourdenche, Wolfgang Froestl, Jörg Kallen, Manuel Koller, Henri Mattes, Joachim Nozulak, David Orain, Johanne Renaud
  • BENZISOXAZOLES
    Publication number: 20110172272
    Abstract: The present invention relates to novel fatty acid esters of the reversible Iloperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
    Type: Application
    Filed: March 14, 2011
    Publication date: July 14, 2011
    Inventors: Joachim Nozulak, Hans O. Kalkman
  • Organic compounds
    Patent number: 7786155
    Abstract: The invention relates to compound of the formula I wherein the substituents are as defined in the specification; in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: August 31, 2010
    Assignee: Novartis AG
    Inventors: Joachim Nozulak, David Orain
  • Benzamides Useful as S1P Receptor Modulators
    Publication number: 20100197753
    Abstract: The invention relates to novel aromatic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, b their use as medicaments and to medicaments comprising them.
    Type: Application
    Filed: May 20, 2008
    Publication date: August 5, 2010
    Inventors: Henri Mattes, Joachim Nozulak, David Orain, Kumlesh K. Dev